MOTS-c UK: The Mitochondrial Peptide Explained

Search for “MOTS-c UK” and you will find a market that has grown around a peptide that is genuinely different from most research compounds. MOTS-c is not a synthetic analog of a human hormone. It is a peptide encoded by mitochondrial DNA, a relatively recent discovery that has opened a new area of research into how mitochondria communicate with the nucleus. The compound is studied for its role in metabolic regulation, exercise response, and cellular stress resistance.

This guide explains what MOTS-c is, what the published research shows, how the FDA’s regulatory posture toward MOTS-c has evolved, and what documentation to verify before sourcing in the UK.

What MOTS-c is

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene. The sequence is MRWQEMGYIFYPRKLR, with a molecular weight of approximately 2,174 Da. It was discovered in 2015 by researchers at the University of Southern California Leonard Davis School of Gerontology. The discovery paper published in Cell Metabolism described MOTS-c as a mitochondrial-derived peptide that regulates metabolic homeostasis by activating AMPK, a central regulator of cellular energy balance.

The mechanism is distinct from other research peptides. MOTS-c translocates to the nucleus in response to metabolic stress and regulates the expression of genes involved in antioxidant response and metabolic adaptation. The compound is studied for its effects on insulin sensitivity, lipid metabolism, and exercise capacity.

What the research shows

The MOTS-c literature is dominated by animal models and in-vitro studies. Human clinical trial data is limited, and no large randomised controlled trials have been published for any indication.

Metabolic regulation

The discovery paper in Cell Metabolism described MOTS-c as a regulator of metabolic homeostasis that activates AMPK. The researchers found that MOTS-c administration improved insulin sensitivity and reduced fat accumulation in mice fed a high-fat diet.

Exercise response

A study published in Nature Communications examined the role of MOTS-c in exercise physiology. The researchers found that the peptide is induced in skeletal muscle in response to exercise and promotes metabolic adaptations that mimic some effects of exercise training.

Cellular stress response

A 2018 study published in Cell Metabolism examined the role of MOTS-c in cellular stress response. The researchers found that the peptide translocates to the nucleus in response to metabolic stress and regulates the expression of genes involved in antioxidant response.

What the research does not establish is a safe and effective dose for any human use. The MOTS-c literature is dominated by animal models and in-vitro studies. The closest human data come from CB4211, a MOTS-c analogue developed by CohBar, which reported topline results from a small Phase 1a/1b study in 2021. MOTS-c itself has no published efficacy results from controlled human trials.

The regulatory status of MOTS-c

MOTS-c is not an FDA-approved drug. It has not received authorization from the MHRA, the FDA, or any other national regulatory body for human use. The compound is sold as a research-use-only laboratory chemical.

In 2023 the FDA placed MOTS-c in Category 2 of bulk drug substances that may present significant safety risks when used in compounding. Category 2 substances are those the agency has identified as presenting potential significant safety risks when used in compounding. In April 2026, the FDA removed 12 peptides from Category 2, including MOTS-c, after their nominations were withdrawn. At its July 2026 meeting, the Pharmacy Compounding Advisory Committee voted 7 to 5, with 2 abstentions, to recommend adding MOTS-c to the 503A bulks list. That vote is advisory only: compounding is not authorized unless the FDA completes formal rulemaking, and MOTS-c remains an unapproved drug.

For researchers, the practical implication is that the regulatory environment around MOTS-c is unsettled. A supplier that claims the compound is legal to sell for human use is misrepresenting the current regulatory posture. A supplier that sells it as a research-use-only chemical and provides analytical documentation is operating within a recognised research supply channel.

How MOTS-c compares to other mitochondrial peptides

MOTS-c is one of several mitochondrial-derived peptides that have been identified in recent years. Understanding how it compares to related compounds helps researchers choose the right tool for a given research question.

The Alta Peptides overview of MOTS-c and epitalon explains the research context for these compounds and the documentation standards that apply.

The researcher’s verification checklist

1. Lot-specific certificate of analysis

A certificate of analysis (COA) is only meaningful if it corresponds to the exact lot you are buying. The COA should list the lot number, the testing laboratory, the report ID, the date the sample was received, and the date the results were published. The Alta Peptides MOTS-c product page lists the current lot documentation alongside the price.

2. Complete analytical panel

A certificate that lists only “purity: 99%” is incomplete. The useful fields are identity by mass spectrometry, purity by HPLC, measured content, endotoxin, and sterility.

3. Named independent laboratory

The testing laboratory should be identified and should be a different organisation from the supplier. In the UK, UKAS accreditation is the recognised mark of competence for testing laboratories.

4. Research-use-only boundary

The listing should not publish dosing, administration, or human-use content. A supplier that maintains the boundary consistently is easier to trust than one that publishes human-use content alongside the RUO label.

How Alta Peptides approaches MOTS-c documentation

Alta Peptides is a UK-based research peptide supplier that publishes lot-specific documentation for each product configuration. The company’s certificates page collects the reports for all products. The longevity and cellular category organises the compounds studied in this research area.

Common questions about MOTS-c

What is MOTS-c?

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA gene. It is studied for its role in metabolic regulation, insulin sensitivity, and cellular stress response. It is sold as a research-use-only laboratory chemical.

Is MOTS-c licensed in the UK?

No. MOTS-c has not received a marketing authorisation from the MHRA. It is sold as a research-use-only laboratory chemical, not as a medicine.

What does the research show?

The discovery paper in Cell Metabolism described MOTS-c as a regulator of metabolic homeostasis that activates AMPK. Subsequent studies have examined its role in exercise response and cellular stress. Human clinical trial data is limited.

What should a MOTS-c COA show?

A complete COA should report identity by mass spectrometry, purity by HPLC with the method stated, measured content or assay value, endotoxin testing, and sterility testing. It should also include the lot number, the testing laboratory’s name, the report ID, and the dates of sample receipt and result reporting.

How do I verify that a COA is real?

Check that the testing laboratory is named and that the report ID can be cross-referenced. Some laboratories publish verification portals where a report ID can be entered to confirm the document’s authenticity.

What is the difference between MOTS-c and humanin?

Both are mitochondrial-derived peptides, but they have different sequences and different mechanisms. MOTS-c is encoded in the 12S rRNA gene and is studied for metabolic regulation. Humanin is encoded in the 16S rRNA gene and is studied for cytoprotective and neuroprotective effects.